At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
Aliskiren 150 mg +3 moredrug
Likely dose
Aliskiren 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-blind, Multiple Dose, Placebo-controlled, Double Dummy Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure
In Brief
A Phase 2 clinical trial evaluating Aliskiren 150 mg, Furosemide 60 mg, and 2 other interventions for Heart Failure. Completed, enrolled 37 participants across 2 sites in 2 countries.
Detailed Summary
This study assessed the interaction between single and multiple doses of aliskiren (150 mg and 300 mg) and furosemide (60 mg) in patients with heart failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesGermany, Lithuania
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedMay 2010
Primary CompletionAug 2011
TodayJul 2026
First PostedMay 18, 2010
Enrollment StartMay 1, 2010
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.1 years ago
Interventions
Aliskiren 150 mgdrug
Aliskiren 150 mg tablet
Furosemide 60 mgdrug
Furosemide 60 mg commercially-available tablets
Placebo for Aliskirendrug
Matching placebo for aliskiren 150 mg and 300 mg
Aliskiren 300 mgdrug
Aliskiren 300 mg tablet